MedTrace Logo

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

NCT06065176 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1188

Last updated 2026-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024 updated vaccine provides better protection from COVID-19 than not getting a vaccine.

If the participant chooses to get a 2023-2024 updated COVID-19 vaccine as part of this study, they will have a 50/50 chance of receiving either the Novavax or Pfizer mRNA vaccine.

If the participant decides not to get a 2023-2024 updated COVID-19 vaccine, the participant can still participate in other study activities.

STUDY ACTIVITIES:

* An online enrollment survey
* An in-person enrollment visit
* Weekly online surveys for 20 weeks
* Weekly COVID-19 tests for 20 weeks
* Additional online surveys if you have COVID-19 symptoms or tested positive for COVID-19.
* Additional COVID-19 tests if you have COVID-19 symptoms or tested positive.
* Online survey questions in the middle and at the end of the study

Conditions

Interventions

BIOLOGICAL

Novavax COVID-19 vaccine (2023-2024 formula XBB containing)

Participants will receive a single dose of the Novavax vaccine.

BIOLOGICAL

Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)

Participants will receive a single dose of the Pfizer vaccine.

Sponsors & Collaborators

  • Westat

    collaborator OTHER

  • Novavax

    collaborator INDUSTRY

  • Sarang K. Yoon, DO, MOH

    lead OTHER

Principal Investigators

  • Sarang K Yoon, DO · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-22
Primary Completion
2024-09-02
Completion
2024-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06065176 on ClinicalTrials.gov